Repare Therapeutics Shareholders Approve Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy RPTX?
Repare Therapeutics announced that its shareholders have approved the acquisition of all of the issued and outstanding common shares of the company by XenoTherapeutics and Xeno Acquisition Corp. by way of a statutory plan of arrangement at the special meeting of Shareholders held on January 16. The arrangement is subject to the approval of the Superior Court of Quebec and other customary closing conditions. The Court hearing for the final order to approve the Arrangement is expected to take place on January 23, and, assuming receipt of the approval of the Court and satisfaction of other customary conditions to closing, the completion of the arrangement is expected to occur on or about January 28.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RPTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RPTX
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Repare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains
- Biotechnology Sector Strength: The biotechnology sector collectively rose by approximately 1.4%, with Repare Therapeutics leading the charge with an 18.9% increase, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Greenwich LifeSciences Follows Suit: Greenwich LifeSciences saw its stock rise by about 16%, further enhancing the overall performance of biotechnology stocks, reflecting positive sentiment among investors and potential market opportunities in the sector.
- Market Sentiment Recovery: The robust performance of biotechnology stocks may signal a recovery in market sentiment, particularly after recent volatility, as investors reassess the value and growth prospects of the industry.
- Increased Investor Attention: As biotechnology stocks rise, investor attention is likely to increase, especially regarding new drug development and innovative technologies, potentially leading to more capital inflow into the sector.
See More
Repare Therapeutics Acquires Gilead's RP-3467 for Up to $30 Million
- Significant Transaction Value: Repare Therapeutics has entered into a definitive agreement with Gilead Sciences to acquire RP-3467 for up to $30 million, including a $25 million upfront payment and a $5 million milestone payment, which strengthens the company's cash flow for future growth.
- Technological Advancement Opportunity: The acquisition of RP-3467, a highly potent small-molecule inhibitor targeting BRCA mutations, is currently undergoing the POLAR Phase 1 trial, which is expected to enhance Repare's competitiveness in the precision oncology market.
- Shareholder Return Expectations: Based on revised estimates, Repare shareholders are projected to receive approximately $2.20 per share upon the closing of the transaction with Xeno Therapeutics, indicating a positive impact from this acquisition on shareholder value.
- Positive Market Reaction: Repare's stock has traded between $0.89 and $2.30 over the past year and is currently up 20.73% in pre-market trading, reaching a new 52-week high, reflecting optimistic market sentiment regarding the acquisition.
See More
Gilead Acquires Repare Therapeutics' RP-3467 for Up to $30 Million
- Acquisition Deal: Gilead Sciences has agreed to acquire Repare Therapeutics' RP-3467 for up to $30 million, including a $25 million upfront payment, showcasing its strong capabilities in oncology research and development.
- Clinical Trial Progress: RP-3467 is currently undergoing the POLAR Phase 1 trial to assess its safety and preliminary efficacy across various cancers, potentially providing Gilead with new treatment options.
- Shareholder Returns: The acquisition is expected to enhance Repare's cash balance, with an estimated cash payment of approximately $2.20 per common share for Repare shareholders, increasing shareholder return potential.
- Market Reaction: Following the announcement, Repare's stock surged 18.43% in premarket trading to $2.56, reaching a new 52-week high, indicating positive market sentiment towards the acquisition.
See More
Halper Sadeh Investigates United Security Bancshares Acquisition by Community West
- Acquisition Investigation: Halper Sadeh LLC is investigating potential violations of federal securities laws related to United Security Bancshares' sale to Community West Bancshares, which involves an exchange of 0.4520 shares of Community West common stock for each share of United Security, potentially impacting shareholder rights.
- Shareholder Rights Protection: The law firm encourages United Security shareholders to contact them promptly to learn about their legal rights and options, ensuring they receive fair compensation and disclosures during the transaction.
- Merger Impact: Upon completion of the merger, Community West shareholders will own approximately 70.6% of the combined company, a significant stake that may affect shareholder voting rights and corporate governance structures.
- Cash Payment Expectations: Shareholders of Repare Therapeutics Inc. are expected to receive a cash payment of $1.82 per share in the sale to XenoTherapeutics, Inc., along with a non-transferable contingent value right, which could influence shareholder return expectations.
See More
Confluent, Inc. to be Sold to IBM for $31.00 per Share Amid Legal Investigation
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Confluent, Inc. (NASDAQ: CFLT) regarding its sale to IBM for $31.00 per share, potentially indicating violations of federal securities laws and fiduciary duties to shareholders, which could impact shareholder rights.
- Shareholder Rights Protection: The law firm encourages Confluent shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other remedies, thereby enhancing potential shareholder returns.
- Investigation of Other Companies: In addition to Confluent, Halper Sadeh is also investigating Eventbrite, Inc. (NYSE: EB) regarding its sale to Bending Spoons for $4.50 per share, indicating a broader legal scrutiny of multiple companies.
- Commitment to Legal Services: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to support investors affected by securities fraud and corporate misconduct, emphasizing their expertise in protecting investor rights.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Repare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains
- Biotechnology Sector Strength: The biotechnology sector collectively rose by approximately 1.4%, with Repare Therapeutics leading the charge with an 18.9% increase, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Greenwich LifeSciences Follows Suit: Greenwich LifeSciences saw its stock rise by about 16%, further enhancing the overall performance of biotechnology stocks, reflecting positive sentiment among investors and potential market opportunities in the sector.
- Market Sentiment Recovery: The robust performance of biotechnology stocks may signal a recovery in market sentiment, particularly after recent volatility, as investors reassess the value and growth prospects of the industry.
- Increased Investor Attention: As biotechnology stocks rise, investor attention is likely to increase, especially regarding new drug development and innovative technologies, potentially leading to more capital inflow into the sector.
See More
Repare Therapeutics Acquires Gilead's RP-3467 for Up to $30 Million
- Significant Transaction Value: Repare Therapeutics has entered into a definitive agreement with Gilead Sciences to acquire RP-3467 for up to $30 million, including a $25 million upfront payment and a $5 million milestone payment, which strengthens the company's cash flow for future growth.
- Technological Advancement Opportunity: The acquisition of RP-3467, a highly potent small-molecule inhibitor targeting BRCA mutations, is currently undergoing the POLAR Phase 1 trial, which is expected to enhance Repare's competitiveness in the precision oncology market.
- Shareholder Return Expectations: Based on revised estimates, Repare shareholders are projected to receive approximately $2.20 per share upon the closing of the transaction with Xeno Therapeutics, indicating a positive impact from this acquisition on shareholder value.
- Positive Market Reaction: Repare's stock has traded between $0.89 and $2.30 over the past year and is currently up 20.73% in pre-market trading, reaching a new 52-week high, reflecting optimistic market sentiment regarding the acquisition.
See More
Gilead Acquires Repare Therapeutics' RP-3467 for Up to $30 Million
- Acquisition Deal: Gilead Sciences has agreed to acquire Repare Therapeutics' RP-3467 for up to $30 million, including a $25 million upfront payment, showcasing its strong capabilities in oncology research and development.
- Clinical Trial Progress: RP-3467 is currently undergoing the POLAR Phase 1 trial to assess its safety and preliminary efficacy across various cancers, potentially providing Gilead with new treatment options.
- Shareholder Returns: The acquisition is expected to enhance Repare's cash balance, with an estimated cash payment of approximately $2.20 per common share for Repare shareholders, increasing shareholder return potential.
- Market Reaction: Following the announcement, Repare's stock surged 18.43% in premarket trading to $2.56, reaching a new 52-week high, indicating positive market sentiment towards the acquisition.
See More
Halper Sadeh Investigates United Security Bancshares Acquisition by Community West
- Acquisition Investigation: Halper Sadeh LLC is investigating potential violations of federal securities laws related to United Security Bancshares' sale to Community West Bancshares, which involves an exchange of 0.4520 shares of Community West common stock for each share of United Security, potentially impacting shareholder rights.
- Shareholder Rights Protection: The law firm encourages United Security shareholders to contact them promptly to learn about their legal rights and options, ensuring they receive fair compensation and disclosures during the transaction.
- Merger Impact: Upon completion of the merger, Community West shareholders will own approximately 70.6% of the combined company, a significant stake that may affect shareholder voting rights and corporate governance structures.
- Cash Payment Expectations: Shareholders of Repare Therapeutics Inc. are expected to receive a cash payment of $1.82 per share in the sale to XenoTherapeutics, Inc., along with a non-transferable contingent value right, which could influence shareholder return expectations.
See More
Confluent, Inc. to be Sold to IBM for $31.00 per Share Amid Legal Investigation
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Confluent, Inc. (NASDAQ: CFLT) regarding its sale to IBM for $31.00 per share, potentially indicating violations of federal securities laws and fiduciary duties to shareholders, which could impact shareholder rights.
- Shareholder Rights Protection: The law firm encourages Confluent shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other remedies, thereby enhancing potential shareholder returns.
- Investigation of Other Companies: In addition to Confluent, Halper Sadeh is also investigating Eventbrite, Inc. (NYSE: EB) regarding its sale to Bending Spoons for $4.50 per share, indicating a broader legal scrutiny of multiple companies.
- Commitment to Legal Services: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to support investors affected by securities fraud and corporate misconduct, emphasizing their expertise in protecting investor rights.
See More
